​

 

SCR Research Partners with Shchelkovo Biocombinat for Exclusive Distribution of Hogivac FMD Vaccine

​

SCR Research is proud to announce an official partnership with Shchelkovo Biocombinat, a leading Russian manufacturer of  vaccine products, for the exclusive distribution of Hogivac in Thailand. Hogivac is a highly effective, inactivated FMD vaccine offering both monovalent and polyvalent options for comprehensive protection against Foot and Mouth Disease (FMD).​

​

Key Features of Hogivac FMD Vaccine:

• High Efficacy: Provides robust and long-lasting immunity against multiple FMD serotypes.

• Inactivated Vaccine: Safe and stable with minimal risk of adverse reactions.

• Available in Monovalent and Polyvalent Formulations: Allows for tailored vaccination strategies based on specific disease challenges and regional needs.

• Proven Safety and Effectiveness: Manufactured under stringent quality control standards at Shchelkovo Biocombinat, a renowned global producer of  vaccines.

​

Benefits of this Partnership:

• Enhanced Disease Control: Enables producers to effectively prevent and control FMD outbreaks, minimizing economic losses and safeguarding animal health.

• Improved Animal Welfare: Protects animals from the debilitating effects of FMD, ensuring their well-being and productivity.

• Increased Market Access: Facilitates access to high-quality FMD vaccines for swine producers across Thailand.

• Strong Technical Support: SCR Research will provide comprehensive technical support to veterinarians and farmers, including vaccination protocols, disease management guidance, and ongoing consultation.

​

This partnership reinforces SCR Research's commitment to delivering innovative and effective veterinary solutions to the Thai market. By providing access to high-quality products like Hogivac, we aim to contribute to the sustainable growth and development of the Thai swine industry.